Home › Compare › JGHAF vs ABBV
JGHAF yields 2.77% · ABBV yields 3.06%● Live data
📍 JGHAF pulled ahead of the other in Year 5
Combined, JGHAF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of JGHAF + ABBV for your $10,000?
Jungheinrich Aktiengesellschaft, through its subsidiaries, manufactures and supplies products and solutions in the fields of warehousing and material handling equipment, automated systems, digital solutions, and matching services worldwide. It operates through Intralogistics and Financial Services segments. The Intralogistics segment develops, produces, sells, and rents new material handling equipment and warehousing equipment products; sale and short-term leasing of used trucks; and provides spare parts, as well as maintenance and repair services. The Financial Services segment engages in the sales financing and usage transfer of material handling and warehousing equipment products. The company's products portfolio includes pedestrian trucks, horizontal and vertical level order pickers, narrow aisle trucks, automated guided vehicles, stacker cranes, load handling equipment, reach trucks, stackers, tow tractors, low lift and double decker trucks, and electric drive trains, as well as pallet trucks; counterbalanced trucks; small-series and customized trucks; powertrain solutions; and electronic control units, lithium-ion batteries, and chargers. It also develops and distributes warehouse and fleet management systems, steering softwares for conveyor systems, and other digital solutions, as well as automation systems; and develops software solutions. The company distributes its products through its direct sales and service network, as well as through dealers. Jungheinrich Aktiengesellschaft was founded in 1953 and is headquartered in Hamburg, Germany.
Full JGHAF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.